FDA approves Eisai and Biogen’s subcutaneous Leqembinews2025-08-29T21:00:40+00:00August 29th, 2025|Endpoints News|
FTC and congressional oversight leader take aim at PBMs againnews2025-08-29T17:56:02+00:00August 29th, 2025|Endpoints News|
Lilly terminates two Phase 2 studies of next-gen oral GLP-1 drugnews2025-08-29T17:47:06+00:00August 29th, 2025|Endpoints News|
FDA takes ‘important step’ toward non-invasive tests for MASH trialsnews2025-08-28T19:25:33+00:00August 28th, 2025|Endpoints News|
Prasad explains why FDA revoked Pfizer’s Covid vaccine EUA for childrennews2025-08-28T13:10:59+00:00August 28th, 2025|Endpoints News|
FDA again rejects Outlook Therapeutics’ version of Avastin for wet AMDnews2025-08-28T11:55:50+00:00August 28th, 2025|Endpoints News|
Novo’s first obesity deal under new CEO is a $550M pact with RNA startup Replicatenews2025-08-28T11:00:46+00:00August 28th, 2025|Endpoints News|
Biopharma returns to MC4R for drugs targeting genetic obesity as well as appetite lossnews2025-08-28T11:00:44+00:00August 28th, 2025|Endpoints News|
Lilly pauses Mounjaro orders in the UK just before raising its price news2025-08-28T10:32:52+00:00August 28th, 2025|Endpoints News|
CDC Director Susan Monarez suddenly departs weeks into the rolenews2025-08-27T22:19:50+00:00August 27th, 2025|Endpoints News|
